| Literature DB >> 31413802 |
An De Decker1, Gwendolyn Vliegen2, Dries Van Rompaey1, Anke Peeraer1, An Bracke2, Line Verckist3, Koen Jansen1, Ruth Geiss-Friedlander4, Koen Augustyns1, Hans De Winter1, Ingrid De Meester2, Anne-Marie Lambeir2, Pieter Van der Veken1.
Abstract
Fibroblast activation protein (FAP) is a proline-selective serine protease. It is hardly expressed in healthy adult tissue but upregulated in tissue remodeling sites associated with several diseases including epithelial cancer types, atherosclerosis, arthritis and fibrosis. Ongoing research aims at clinical implementation of FAP as a biomarker for these diseases. Several immunochemical methods that quantify FAP expression have been reported. An alternative/complementary approach focuses on quantification of FAP's enzymatic activity. Developing an activity-based assay for FAP has nonetheless proven challenging because of selectivity issues with respect to prolyl oligopeptidase (PREP). Here, we present substrate-type FAP probes that are structurally derived from a FAP-inhibitor (UAMC1110) that we published earlier. Both cleavage efficiency and FAP-selectivity of the best compounds in the series equal or surpass the most advanced peptide-based FAP substrates reported to date. Finally, proof-of-concept is provided that 4-aminonaphthol containing probes can spatially localize FAP activity in biological samples.Entities:
Year: 2019 PMID: 31413802 PMCID: PMC6691567 DOI: 10.1021/acsmedchemlett.9b00191
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345